GlassScriptPhysician profile
Michael Y Cho
NPI 1487970950
$4,533.78
in general payments reported to CMS, 2019-2025
14 companies · $865 in 2025
The $865 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $428 · 2021: $269 · 2022: $548 · 2023: $904 · 2024: $768 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.98 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $981.83 | 2022-2025 | Opdivo, Reblozyl, Breyanzi |
| Ipsen Biopharmaceuticals, INC | $817.70 | 2019-2025 | Tazverik, Onivyde |
| Seagen INC. | $311.86 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $297.15 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $293.70 | 2019-2024 | |
| Aadi Bioscience, INC. | $285.67 | 2022-2023 | Fyarro |
| Incyte Corporation | $250.43 | 2025 | Monjuvi, Zynyz |
| Astellas Pharma US INC | $244.32 | 2023-2024 | Padcev |
| Celgene Corporation | $221.19 | 2019-2023 | Pomalyst |
| Alexion Pharmaceuticals, INC. | $207.70 | 2025 | Soliris |
| Emd Serono, INC. | $206.47 | 2023-2024 | Bavencio |
| Rigel Pharmaceuticals, INC. | $168.09 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Stryker Corporation | $133.60 | 2023 | Xpress Ent Dilation System, Spy-Phi System, 1788 |
| Novartis Pharmaceuticals Corporation | $114.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.